

Myotonic Muscular Dystrophy (DMD) Treatments Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/M91DB7A0739BEN.html>

Date: February 2022

Pages: 67

Price: US\$ 3,250.00 (Single User License)

ID: M91DB7A0739BEN

Abstracts

This report contains market size and forecasts of Myotonic Muscular Dystrophy (DMD) Treatments in Global, including the following market information:

Global Myotonic Muscular Dystrophy (DMD) Treatments Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Myotonic Muscular Dystrophy (DMD) Treatments market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Medications Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Myotonic Muscular Dystrophy (DMD) Treatments include Pfizer, Inc., Eli Lilly and Company, Mylan Pharmaceuticals Inc., Wockhardt Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, BioMarin Pharmaceutical, Inc., Asklepios Kliniken GmbH and Hoveround Corporation and etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Myotonic Muscular Dystrophy (DMD) Treatments companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry

trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Myotonic Muscular Dystrophy (DMD) Treatments Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Myotonic Muscular Dystrophy (DMD) Treatments Market Segment Percentages, by Type, 2021 (%)

Medications

Rehabilitative Therapies

Devices

Surgeries

Global Myotonic Muscular Dystrophy (DMD) Treatments Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Myotonic Muscular Dystrophy (DMD) Treatments Market Segment Percentages, by Application, 2021 (%)

Hospitals

Specialty Clinics

Ambulatory Surgery Centers

Global Myotonic Muscular Dystrophy (DMD) Treatments Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Myotonic Muscular Dystrophy (DMD) Treatments Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Myotonic Muscular Dystrophy (DMD) Treatments revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Myotonic Muscular Dystrophy (DMD) Treatments revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Pfizer, Inc.

Eli Lilly and Company

Mylan Pharmaceuticals Inc.

Wockhardt Ltd.

Teva Pharmaceutical Industries Ltd.

Novartis AG

BioMarin Pharmaceutical, Inc.

Asklepios Kliniken GmbH

Hoveround Corporation

Siemens Healthcare

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Myotonic Muscular Dystrophy (DMD) Treatments Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL MYOTONIC MUSCULAR DYSTROPHY (DMD) TREATMENTS OVERALL MARKET SIZE

- 2.1 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size: 2021 VS 2028
- 2.2 Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Myotonic Muscular Dystrophy (DMD) Treatments Players in Global Market
- 3.2 Top Global Myotonic Muscular Dystrophy (DMD) Treatments Companies Ranked by Revenue
- 3.3 Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue by Companies
- 3.4 Top 3 and Top 5 Myotonic Muscular Dystrophy (DMD) Treatments Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Myotonic Muscular Dystrophy (DMD) Treatments Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Myotonic Muscular Dystrophy (DMD) Treatments Players in Global Market
 - 3.6.1 List of Global Tier 1 Myotonic Muscular Dystrophy (DMD) Treatments

Companies

3.6.2 List of Global Tier 2 and Tier 3 Myotonic Muscular Dystrophy (DMD) Treatments

Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size Markets, 2021 & 2028

4.1.2 Medications

4.1.3 Rehabilitative Therapies

4.1.4 Devices

4.1.5 Surgeries

4.2 By Type - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue & Forecasts

4.2.1 By Type - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2022

4.2.2 By Type - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2023-2028

4.2.3 By Type - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2021 & 2028

5.1.2 Hospitals

5.1.3 Specialty Clinics

5.1.4 Ambulatory Surgery Centers

5.2 By Application - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue & Forecasts

5.2.1 By Application - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2022

5.2.2 By Application - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2023-2028

5.2.3 By Application - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2021 & 2028

6.2 By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue & Forecasts

6.2.1 By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2022

6.2.2 By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2023-2028

6.2.3 By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2028

6.3.2 US Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.3.3 Canada Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.3.4 Mexico Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2028

6.4.2 Germany Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4.3 France Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4.4 U.K. Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4.5 Italy Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4.6 Russia Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4.7 Nordic Countries Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.4.8 Benelux Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2028

6.5.2 China Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.5.3 Japan Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.5.4 South Korea Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.5.5 Southeast Asia Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.5.6 India Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2028

6.6.2 Brazil Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.6.3 Argentina Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2028

6.7.2 Turkey Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.7.3 Israel Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.7.4 Saudi Arabia Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

6.7.5 UAE Myotonic Muscular Dystrophy (DMD) Treatments Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Pfizer, Inc.

7.1.1 Pfizer, Inc. Corporate Summary

7.1.2 Pfizer, Inc. Business Overview

7.1.3 Pfizer, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings

7.1.4 Pfizer, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)

7.1.5 Pfizer, Inc. Key News

7.2 Eli Lilly and Company

7.2.1 Eli Lilly and Company Corporate Summary

7.2.2 Eli Lilly and Company Business Overview

7.2.3 Eli Lilly and Company Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings

7.2.4 Eli Lilly and Company Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)

7.2.5 Eli Lilly and Company Key News

7.3 Mylan Pharmaceuticals Inc.

- 7.3.1 Mylan Pharmaceuticals Inc. Corporate Summary
- 7.3.2 Mylan Pharmaceuticals Inc. Business Overview
- 7.3.3 Mylan Pharmaceuticals Inc. Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings
- 7.3.4 Mylan Pharmaceuticals Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)
- 7.3.5 Mylan Pharmaceuticals Inc. Key News
- 7.4 Wockhardt Ltd.
- 7.4.1 Wockhardt Ltd. Corporate Summary
- 7.4.2 Wockhardt Ltd. Business Overview
- 7.4.3 Wockhardt Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings
- 7.4.4 Wockhardt Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)
- 7.4.5 Wockhardt Ltd. Key News
- 7.5 Teva Pharmaceutical Industries Ltd.
- 7.5.1 Teva Pharmaceutical Industries Ltd. Corporate Summary
- 7.5.2 Teva Pharmaceutical Industries Ltd. Business Overview
- 7.5.3 Teva Pharmaceutical Industries Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings
- 7.5.4 Teva Pharmaceutical Industries Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)
- 7.5.5 Teva Pharmaceutical Industries Ltd. Key News
- 7.6 Novartis AG
- 7.6.1 Novartis AG Corporate Summary
- 7.6.2 Novartis AG Business Overview
- 7.6.3 Novartis AG Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings
- 7.6.4 Novartis AG Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)
- 7.6.5 Novartis AG Key News
- 7.7 BioMarin Pharmaceutical, Inc.
- 7.7.1 BioMarin Pharmaceutical, Inc. Corporate Summary
- 7.7.2 BioMarin Pharmaceutical, Inc. Business Overview
- 7.7.3 BioMarin Pharmaceutical, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Major Product Offerings
- 7.7.4 BioMarin Pharmaceutical, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)
- 7.7.5 BioMarin Pharmaceutical, Inc. Key News

7.8 Asklepios Kliniken GmbH

7.8.1 Asklepios Kliniken GmbH Corporate Summary

7.8.2 Asklepios Kliniken GmbH Business Overview

7.8.3 Asklepios Kliniken GmbH Myotonic Muscular Dystrophy (DMD) Treatments

Major Product Offerings

7.8.4 Asklepios Kliniken GmbH Myotonic Muscular Dystrophy (DMD) Treatments

Revenue in Global Market (2017-2022)

7.8.5 Asklepios Kliniken GmbH Key News

7.9 Hoveround Corporation

7.9.1 Hoveround Corporation Corporate Summary

7.9.2 Hoveround Corporation Business Overview

7.9.3 Hoveround Corporation Myotonic Muscular Dystrophy (DMD) Treatments Major

Product Offerings

7.9.4 Hoveround Corporation Myotonic Muscular Dystrophy (DMD) Treatments

Revenue in Global Market (2017-2022)

7.9.5 Hoveround Corporation Key News

7.10 Siemens Healthcare

7.10.1 Siemens Healthcare Corporate Summary

7.10.2 Siemens Healthcare Business Overview

7.10.3 Siemens Healthcare Myotonic Muscular Dystrophy (DMD) Treatments Major

Product Offerings

7.10.4 Siemens Healthcare Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global Market (2017-2022)

7.10.5 Siemens Healthcare Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Myotonic Muscular Dystrophy (DMD) Treatments Market Opportunities & Trends in Global Market

Table 2. Myotonic Muscular Dystrophy (DMD) Treatments Market Drivers in Global Market

Table 3. Myotonic Muscular Dystrophy (DMD) Treatments Market Restraints in Global Market

Table 4. Key Players of Myotonic Muscular Dystrophy (DMD) Treatments in Global Market

Table 5. Top Myotonic Muscular Dystrophy (DMD) Treatments Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Share by Companies, 2017-2022

Table 8. Global Companies Myotonic Muscular Dystrophy (DMD) Treatments Product Type

Table 9. List of Global Tier 1 Myotonic Muscular Dystrophy (DMD) Treatments Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Myotonic Muscular Dystrophy (DMD) Treatments Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Myotonic Muscular Dystrophy (DMD) Treatments Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments

Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments

Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Myotonic Muscular Dystrophy (DMD) Treatments

Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Myotonic Muscular Dystrophy (DMD) Treatments

Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Myotonic Muscular Dystrophy (DMD) Treatments

Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Myotonic Muscular Dystrophy (DMD) Treatments

Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Myotonic Muscular Dystrophy (DMD) Treatments Revenue,
(US\$, Mn), 2017-2022

Table 25. By Region - Asia Myotonic Muscular Dystrophy (DMD) Treatments Revenue,
(US\$, Mn), 2023-2028

Table 26. By Country - South America Myotonic Muscular Dystrophy (DMD) Treatments
Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Myotonic Muscular Dystrophy (DMD) Treatments
Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Myotonic Muscular Dystrophy (DMD)
Treatments Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Myotonic Muscular Dystrophy (DMD)
Treatments Revenue, (US\$, Mn), 2023-2028

Table 30. Pfizer, Inc. Corporate Summary

Table 31. Pfizer, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Product
Offerings

Table 32. Pfizer, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$,
Mn), (2017-2022)

Table 33. Eli Lilly and Company Corporate Summary

Table 34. Eli Lilly and Company Myotonic Muscular Dystrophy (DMD) Treatments
Product Offerings

Table 35. Eli Lilly and Company Myotonic Muscular Dystrophy (DMD) Treatments
Revenue (US\$, Mn), (2017-2022)

Table 36. Mylan Pharmaceuticals Inc. Corporate Summary

Table 37. Mylan Pharmaceuticals Inc. Myotonic Muscular Dystrophy (DMD) Treatments
Product Offerings

Table 38. Mylan Pharmaceuticals Inc. Myotonic Muscular Dystrophy (DMD) Treatments
Revenue (US\$, Mn), (2017-2022)

Table 39. Wockhardt Ltd. Corporate Summary

Table 40. Wockhardt Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 41. Wockhardt Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

Table 42. Teva Pharmaceutical Industries Ltd. Corporate Summary

Table 43. Teva Pharmaceutical Industries Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 44. Teva Pharmaceutical Industries Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

Table 45. Novartis AG Corporate Summary

Table 46. Novartis AG Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 47. Novartis AG Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

Table 48. BioMarin Pharmaceutical, Inc. Corporate Summary

Table 49. BioMarin Pharmaceutical, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 50. BioMarin Pharmaceutical, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

Table 51. Asklepios Kliniken GmbH Corporate Summary

Table 52. Asklepios Kliniken GmbH Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 53. Asklepios Kliniken GmbH Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

Table 54. Hoveround Corporation Corporate Summary

Table 55. Hoveround Corporation Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 56. Hoveround Corporation Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

Table 57. Siemens Healthcare Corporate Summary

Table 58. Siemens Healthcare Myotonic Muscular Dystrophy (DMD) Treatments Product Offerings

Table 59. Siemens Healthcare Myotonic Muscular Dystrophy (DMD) Treatments Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Myotonic Muscular Dystrophy (DMD) Treatments Segment by Type in 2021

Figure 2. Myotonic Muscular Dystrophy (DMD) Treatments Segment by Application in 2021

Figure 3. Global Myotonic Muscular Dystrophy (DMD) Treatments Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Myotonic Muscular Dystrophy (DMD) Treatments Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Myotonic Muscular Dystrophy (DMD) Treatments Revenue in 2021

Figure 8. By Type - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 9. By Application - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 10. By Region - Global Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 11. By Country - North America Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 12. US Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 16. Germany Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 17. France Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

2017-2028

Figure 20. Russia Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 24. China Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 28. India Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 30. Brazil Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Myotonic Muscular Dystrophy (DMD) Treatments Revenue Market Share, 2017-2028

Figure 33. Turkey Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Myotonic Muscular Dystrophy (DMD) Treatments Revenue, (US\$, Mn), 2017-2028

Figure 37. Pfizer, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Eli Lilly and Company Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Mylan Pharmaceuticals Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Wockhardt Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Teva Pharmaceutical Industries Ltd. Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Novartis AG Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. BioMarin Pharmaceutical, Inc. Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Asklepios Kliniken GmbH Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Hoveround Corporation Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 46. Siemens Healthcare Myotonic Muscular Dystrophy (DMD) Treatments Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Myotonic Muscular Dystrophy (DMD) Treatments Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/M91DB7A0739BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M91DB7A0739BEN.html>